Status:
COMPLETED
Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Pain, Postoperative
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To validate the analgesic efficacy and safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Eligibility Criteria
Inclusion
- Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia
- Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale
Exclusion
- A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical structures
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00150280
Start Date
October 1 2004
End Date
July 1 2005
Last Update
March 3 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Shenyang, Liaoning, China, 110001
2
Pfizer Investigational Site
Beijing, China, 100020
3
Pfizer Investigational Site
Beijing, China, 100034
4
Pfizer Investigational Site
Beijing, China, 100083